Additional file 3: of Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer

Supplementary method. The synthesis details of BK011. (DOCX 13 kb

Additional file 1: of Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer

Table S1. The distribution of Q20 and Q30 representing quality control of sequencing. (DOCX 14 kb

Additional file 2: of Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer

Figure S1. The work flow of gene variation calling. (DOCX 195 kb

Additional file 8: of Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer

Table S5. Summary of SNVs, InDels, CNVs, and fusions of the 50 xenografts by targeted sequencing. (DOCX 14 kb

Additional file 7: of Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer

Table S4. The clinicalpathological characteristics of xenografts. (DOCX 14 kb

Additional file 9: of Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer

Table S6. The expression of PD-L1 in EBV-positive and EBV-negative xenografts. (DOCX 12 kb

Additional file 4: of Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer

Figure S2. In vitro proliferation inhibitory activity of DiFi cells. (DOCX 18 kb

Additional file 6: of Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer

Table S3. The list of genes sequenced in this study. (DOCX 16 kb